Immuron Limited (NASDAQ: IMRN) reported third-quarter sales of AUD$1.5 million for its Travelan product, representing a 16% increase compared to the same period last year, according to unaudited figures released by the company.

The Australian biopharmaceutical company's year-to-date sales through March 2026 reached AUD$5.7 million, up 7% from the prior comparative period. Travelan is an over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract.

Australia remained the company's largest market, generating AUD$0.9 million in third-quarter sales, a 15% increase year-over-year. Australian year-to-date sales totaled AUD$4.2 million, up 14% from the previous year.

Canadian operations showed notable quarterly improvement with sales of AUD$0.1 million, representing an 82% increase from the prior quarter and more than 100% growth compared to the same quarter last year. The company attributed the growth to initial sales to Jean Coutu, a pharmacy group in Quebec.

U.S. sales reached AUD$0.5 million in the third quarter, up 1% from the prior year period, with year-to-date sales of AUD$1.3 million representing a 10% increase.

The company cited several factors contributing to growth, including digital marketing campaigns, expanded retail presence, and increased travel to Southeast Asia from Australian consumers. In the U.S., initiatives included improvements to the Amazon store presence and enhanced social media marketing.

Travelan is sold as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the United States. The product is designed to reduce the risk of traveler's diarrhea through orally administered passive immunotherapy.